A detailed history of Continuum Advisory, LLC transactions in Incyte Corp stock. As of the latest transaction made, Continuum Advisory, LLC holds 580 shares of INCY stock, worth $39,927. This represents 0.0% of its overall portfolio holdings.

Number of Shares
580
Previous 54,090 98.93%
Holding current value
$39,927
Previous $3.28 Million 98.84%
% of portfolio
0.0%
Previous 0.48%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$57.33 - $68.61 $3.07 Million - $3.67 Million
-53,510 Reduced 98.93%
580 $38,000
Q2 2024

Jul 19, 2024

BUY
$51.18 - $63.75 $85,061 - $105,952
1,662 Added 3.17%
54,090 $3.28 Million
Q1 2024

May 10, 2024

BUY
$56.55 - $66.59 $1.3 Million - $1.53 Million
22,988 Added 78.08%
52,428 $2.99 Million
Q4 2023

Feb 14, 2024

BUY
$52.16 - $64.19 $391,825 - $482,195
7,512 Added 34.26%
29,440 $1.85 Million
Q3 2023

Nov 13, 2023

BUY
$57.77 - $65.93 $1.27 Million - $1.45 Million
21,928 New
21,928 $1.27 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Continuum Advisory, LLC Portfolio

Follow Continuum Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Continuum Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Continuum Advisory, LLC with notifications on news.